[Lipegfilgrastim - long acting G-CSF in prevention of chemotherapy-induced neutropenia]. / Lipegfilgrasztim hosszú hatású G-CSF a kemoterápia indukálta neutropénia megelõzésében.
Magy Onkol
; 62(3): 195-200, 2018 Sep 26.
Article
em Hu
| MEDLINE
| ID: mdl-30256886
ABSTRACT
One of the most dangerous complications of bone marrow suppression due to chemotherapy is febrile neutropenia. The treatment of the affected patients is a multidisciplinary task. In addition to chemotherapy, adequate G-CSF therapy as a primary or secondary prophylaxis can be used to prevent a large part of febrile neutropenic events. Before each chemotherapy cycle, the risk of febrile neutropenia should be evaluated, taking into account the chemotherapeutic combination and patient-specific parameters. Appropriate antibiotic and G-CSF therapy initiated in the course of febrile neutropenia is essential for the success of the therapy. Long-acting G-CSF therapy for secondary prevention, lipegfilgrastim is effective, safe and simple dosing for the patient. The oncologists can reach treatment success in the patient's therapy if he or she provides the patient the adequate supportive medications at the appropriate time. Lipegfilgrastim is not a biosimilar, but a new molecule created by a two-step empiric glycopegylation process.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Polietilenoglicóis
/
Filgrastim
/
Neutropenia
/
Antineoplásicos
Limite:
Humans
Idioma:
Hu
Revista:
Magy Onkol
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Hungria